Bonn, Germany – Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn (UKB) and Clinician Scientist of the BMBF-funded ACCENT program and PD Dr. Markus Eckstein, senior physician at the Institute of Pathology at the Uniklinikum Erlangen of the...
Latest News
BUFFALO, NY – A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 1, entitled, “Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.” Research has demonstrated that...
This study is led by Prof. Lixiang Xue (Cancer Center of Peking University Third Hospital Center of Basic Medical Research, Peking University Third Hospital). In ovarian cancer, the abnormal expression of various metabolic enzymes in the metabolism of polyunsaturated fatty acids (PUFA) is involved in the development of tumor and...
Shannon, Ireland – Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective approach to developing novel targeted therapies for cancer and other chronic diseases. The MYC family of proteins, which...
SOUTH PLAINFIELD, N.J. – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, “Gene Therapy in the Putamen for Curing AADC Deficiency and Parkinson’s Disease,” in the European Molecular Biology Organization Journal. The paper describes a pioneering approach that delivers gene therapy to a specific part of the brain...
OSLO, Norway – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that the European Patent Office has granted EU Patent no EP3402889. The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma. Torbjørn Furuseth,...
Basel, June 5, 2009 – New data show that at 12 months newly diagnosed patients taking Tasigna® (nilotinib) to treat a life-threatening form of chronic myeloid leukemia (CML) had rapid responses and a deep reduction in the amount of the abnormal protein that causes this disease. “Tasigna now demonstrates potential...
DALLAS, Texas — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to...
CTA approved by Health Canada in November 2021; IND approved and open in 2019 Queen’s University selected as initial clinical site under the direction of Dr. Jagdeep Wahlia, principal investigator PPT1 enzyme activity of 5% or greater normalizes survival and significantly improves clinical phenotype based on natural history data Preliminary...
DALLAS, TX — Taysha Gene Therapies, Inc., a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will present clinical data on its TSHA-102 program in evaluation for Rett syndrome during...